Glenn Rockman, Founder and Managing Partner at Adjuvant Capital
Glenn is Founder and Managing Partner at Adjuvant Capital, a life sciences investment firm focused on high-burden and neglected public health challenges. Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director. He is still active on a number of GHIF projects, including board seats on a number of innovative life sciences companies such as Univercells, Themis, and EuBiologics (listed on KOSDAQ in 2017: 206650.KQ). Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018.
At Adjuvant, Glenn oversees the firm’s investments in X-Vax (board observer), Themis (board member), and Codagenix (board member), in addition to his InDevR board seat. He is also actively engaged with board member seats at the Research Investment for Global Health Technology Fund (RIGHT Fund) and WaterEquity, where he is a champion of new approaches to financing progress toward achieving the UN Sustainable Development Goals.
Prior to his GHIF/Adjuvant roles, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.